Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare Risankizumab (Skyrizi) and Vedolizumab (Entyvio) — clinical data, side effects, and patient experiences.
Skyrizi · Biologic (IL-23 Inhibitor)
How it works
Humanized monoclonal antibody that selectively binds to the p19 subunit of IL-23, inhibiting IL-23-dependent inflammatory signalling.
Approved for
Entyvio · Integrin Inhibitor
How it works
Humanized monoclonal antibody that binds alpha4-beta7 integrin, blocking lymphocyte trafficking to gut-associated lymphoid tissue.
Approved for
Estimated frequency (%) based on clinical trial data
No head-to-head clinical studies found for Risankizumab vs Vedolizumab.
Risankizumab is a Biologic (IL-23 Inhibitor), while Vedolizumab belongs to the Integrin Inhibitor class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. Risankizumab is administered via Subcutaneous, whereas Vedolizumab uses Intravenous or Subcutaneous. Route of administration can affect onset of action and patient adherence.
Both medications are approved for Crohn's Disease. When two drugs treat the same condition, the choice between them often depends on the patient's medical history, other medications, tolerability, and prescriber preference.
Risankizumab carries 2 FDA warnings. Vedolizumab carries 3 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.